High-dose steroid treatment for severe COVID raises clot and bleeding risks

A major clinical trial found that doubling the standard dexamethasone dose for critically ill COVID patients increased both blood clots and bleeding complications. The finding could reshape treatment protocols in hospitals and influence purchasing decisions for intensive care units managing severe respiratory illness.

Originaltitel: Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19-a post hoc analysis of the randomized, blinded COVID STEROID 2 trial